Septerna, Inc. SEPN 深 沪
等待开盘 04-02 09:30:00 美东时间
24.37
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 24.37
- 总市值 10.94亿
- 52周最高 32.63
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.51
- 委 比 0.00%
- 总股本 4490.64万
- 历史最高 32.63
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.17
- 每 手 1
- 风险率 7.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
JP Morgan Maintains Overweight on Septerna, Raises Price Target to $38
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the price target from $34 to $38.
03-25 02:13
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Truist Securities Maintains Buy on Septerna, Raises Price Target to $35
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $34 to $35.
03-11 21:52
Septerna Files Shelf Registration For Future Offerings Of Stock, Debt, Warrants, And Units
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or more series or classes, our common stock, preferred stock, debt securities, warrants and/or units, in any combination,
03-11 04:34
Earnings Summary: Septerna Q4
Septerna (NASDAQ:SEPN) announced its Q4 earnings on Monday, March 9, 2026 at 08...
03-10 04:16
Septerna Q4 EPS $(0.24) Misses $0.03 Estimate, Sales $24.118M Miss $32.667M Estimate
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $0.03 by 988.89 percent. This is a 62.5 percent increase over losses of $(0.64) per share from the same
03-10 04:14
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Septerna Inc. announced positive Phase 1 results for SEP-631, a potential treatment for mast cell diseases, supporting its Phase 2 development in CSU starting later this year. SEP-479, a PTH1R agonist for hypoparathyroidism, is on track to begin Phase 1 trials in early 2026. The company reported a strong financial position with $548.7 million in cash and expects its runway to support operations into at least 2029.
03-09 20:05
Septerna Chief People Officer Samira Shaikhly Disposes of Common Shares
Septerna Chief People Officer Samira Shaikhly Disposes of Common Shares Samira Shaikhly, Chief People Officer of Septerna Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies
03-05 08:01
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
